Tommy B. Andersson

COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES

Xueqing Li, Tommy B. Andersson, Marie M. Ahlström et al. · Drug Metabolism and Disposition · 2004 · 636 citations

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

Andreas Kindmark, A Jawaid, Chris Harbron et al. · The Pharmacogenomics Journal · 2007 · 365 citations

Genetic Epidemiology, Immunology, Pathology +17

Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies

Kajsa P. Kanebratt, Tommy B. Andersson · Drug Metabolism and Disposition · 2008 · 341 citations

Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory Region

Anna Westlind, Lena Löfberg, Niclas Tindberg et al. · Biochemical and Biophysical Research Communications · 1999 · 300 citations

Transcriptional Regulation, Systems Biology, Hepatology +11

Amodiaquine Clearance and Its Metabolism to N-Desethylamodiaquine Is Mediated by CYP2C8: A New High Affinity and Turnover Enzyme-Specific Probe Substrate

Xueqing Li, Anders Björkman, Tommy B. Andersson et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 284 citations